Skip to main content


Phase2Phase offers to assist not only with CMC services. In validated investment cases we are open to share risks in terms of funding. Our investments are made separately or as a part of an investor network.

Our current portfolio companies are:


Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate that provides a novel mechanism of action and is therefore assumed to have less adverse effects than current treatments in use.

Athera Biotechnologies AB is a dynamic company with a vision to address the need for improved treatment of vascular disease patients and is now pursuing clinical development with its anti-inflammatory antibody.